Free Trial

Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis

Y-mAbs Therapeutics logo
$8.52 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$8.52 0.00 (0.00%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Y-mAbs Therapeutics Stock (NASDAQ:YMAB)

Key Stats

Today's Range
$8.51
$8.54
50-Day Range
$4.19
$8.52
52-Week Range
$3.55
$16.11
Volume
1.24 million shs
Average Volume
1.31 million shs
Market Capitalization
$385.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.16
Consensus Rating
Hold

Company Overview

Y-mAbs Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

YMAB MarketRank™: 

Y-mAbs Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 496th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Y-mAbs Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.08, and is based on 1 buy rating, 8 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Y-mAbs Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Y-mAbs Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.59) per share.

  • Price to Book Value per Share Ratio

    Y-mAbs Therapeutics has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Y-mAbs Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.35% of the float of Y-mAbs Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Y-mAbs Therapeutics has recently increased by 80,222.58%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Y-mAbs Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Y-mAbs Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.35% of the float of Y-mAbs Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Y-mAbs Therapeutics has recently increased by 80,222.58%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Y-mAbs Therapeutics has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 24 news articles for Y-mAbs Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    1 people have searched for YMAB on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 5 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -58% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Y-mAbs Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.70% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    70.85% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Y-mAbs Therapeutics' insider trading history.
Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

YMAB Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Hold Rating from Jones Trading
See More Headlines

YMAB Stock Analysis - Frequently Asked Questions

Y-mAbs Therapeutics' stock was trading at $7.83 at the beginning of 2025. Since then, YMAB shares have increased by 8.8% and is now trading at $8.52.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.10. The firm earned $20.90 million during the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 31.84% and a negative trailing twelve-month return on equity of 30.59%.
Read the conference call transcript
.

Y-mAbs Therapeutics (YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Top institutional shareholders of Y-mAbs Therapeutics include Los Angeles Capital Management LLC (0.02%) and CWM LLC (0.02%). Insiders that own company stock include Biotech Aps Wg, Johan Wedell-Wedellsborg, Bo Kruse, Thomas Gad, Michael J Rossi, Vignesh Rajah and Joris Wilms.
View institutional ownership trends
.

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Y-mAbs Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Jabil (JBL).

Company Calendar

Last Earnings
5/13/2025
Today
8/07/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:YMAB
CIK
1722964
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

High Price Target
$25.00
Low Price Target
$3.00
Potential Upside/Downside
+30.9%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.67 million
Net Margins
-31.84%
Pretax Margin
-32.18%
Return on Equity
-30.59%
Return on Assets
-22.70%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.77
Quick Ratio
4.35

Sales & Book Value

Annual Sales
$88.66 million
Price / Sales
4.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.05 per share
Price / Book
4.16

Miscellaneous

Outstanding Shares
45,284,000
Free Float
36,363,000
Market Cap
$386.05 million
Optionable
Optionable
Beta
0.57

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:YMAB) was last updated on 8/7/2025 by MarketBeat.com Staff
From Our Partners